Facebook tracking pixel
R97.20
ICD-10-CM
Abnormal PSA

Understanding Abnormal PSA, Elevated PSA, and abnormal PSA readings is crucial for accurate healthcare documentation and medical coding. Learn about the clinical significance of an abnormal PSA test result, including diagnosis considerations and relevant medical codes for proper clinical documentation. This resource provides essential information for healthcare professionals on interpreting and documenting abnormal PSA findings.

Also known as

Elevated PSA
Abnormal PSA reading

Diagnosis Snapshot

Key Facts
  • Definition : Higher than normal prostate-specific antigen level in the blood, potentially indicating prostate problems.
  • Clinical Signs : Often asymptomatic, but may include urinary problems or erectile dysfunction if linked to prostate disease.
  • Common Settings : Primary care clinics, urology departments, and prostate cancer screening centers.

Related ICD-10 Code Ranges

Complete code families applicable to AAPC R97.20 Coding
R79.89

Abnormal findings of blood chemistry

This code signifies other specified abnormal findings in blood chemistry.

N42.3

Enlarged prostate without inflammation

Elevated PSA may suggest benign prostatic hyperplasia (BPH).

C61

Malignant neoplasm of prostate

PSA elevation can be a marker of prostate cancer.

Code-Specific Guidance

Decision Tree for

Follow this step-by-step guide to choose the correct ICD-10 code.

Is the abnormal PSA due to a known malignancy?

Code Comparison

Related Codes Comparison

When to use each related code

Description
Elevated prostate-specific antigen levels.
Enlarged prostate gland, often benign.
Cancer of the prostate gland.

Documentation Best Practices

Documentation Checklist
  • Document PSA level with units (e.g., ng/mL)
  • Specify testing method used for PSA
  • Date of the PSA test
  • Patient age and digital rectal exam findings
  • Correlation with other prostate health indicators

Coding and Audit Risks

Common Risks
  • Unspecified PSA Type

    Coding elevated PSA without specifying total, free, or complex PSA can lead to claim denials and inaccurate quality reporting. Affects medical coding, CDI, healthcare compliance.

  • Lack of Clinical Support

    Elevated PSA alone lacks specificity. Coding requires supporting documentation of medical necessity and correlation with other findings for proper risk adjustment. Impacts medical coding, CDI, and healthcare compliance.

  • Missing Follow-up Codes

    Failing to code subsequent diagnostic workup (e.g., biopsies, imaging) after abnormal PSA can lead to lost reimbursement and inaccurate clinical picture. Relevant for medical coding, CDI, healthcare compliance.

Mitigation Tips

Best Practices
  • Document PSA testing rationale: ICD-10 Z12.5, CPT 86316. Improve CDI.
  • Evaluate BPH, prostatitis: SNOMED CT 60004, ICD-10 N41.1, N41.0. HCC coding.
  • Consider age-specific PSA ranges for accurate interpretation. Risk adjustment.
  • Repeat PSA test, if indicated, per guidelines for abnormal PSA levels. Compliance.
  • Correlate PSA with DRE findings for better prostate cancer detection. HCC/RAF.

Clinical Decision Support

Checklist
  • Verify PSA value > 4 ng/mL (age-adjusted ranges). ICD-10 R97.2
  • Review patient history: BPH, prostatitis, UTI? SNOMED CT 73999001
  • DRE performed? Document findings. CPT 74200
  • Consider shared decision-making for next steps. LOINC 34133-9

Reimbursement and Quality Metrics

Impact Summary
  • **Reimbursement and Quality Metrics Impact Summary: Abnormal PSA (Elevated PSA, Abnormal PSA reading)**
  • **Keywords:** Medical billing, coding accuracy, ICD-10 R79.89, CPT 84153, PSA screening, hospital reporting, quality measures, reimbursement impact, denial management
  • **Impact 1:** Accurate coding (ICD-10 R79.89, CPT 84153) maximizes reimbursement for PSA testing.
  • **Impact 2:** Proper documentation supports medical necessity, reducing claim denials.
  • **Impact 3:** PSA screening data impacts quality reporting metrics for early prostate cancer detection.

Streamline Your Medical Coding

Let S10.AI help you select the most accurate ICD-10 codes. Our AI-powered assistant ensures compliance and reduces coding errors.

Frequently Asked Questions

Common Questions and Answers

Q: What are the most common differential diagnoses for an abnormal PSA level besides prostate cancer in an asymptomatic older male patient?

A: While an abnormal PSA, including an elevated PSA or abnormal PSA reading, is often associated with prostate cancer, particularly in older male patients, it's crucial to consider other potential causes in asymptomatic individuals. Benign prostatic hyperplasia (BPH) is a frequent contributor to elevated PSA levels. Prostatitis, both acute and chronic, can also cause a rise in PSA. Other factors, such as recent ejaculation, urinary tract infection (UTI), certain medications, and even vigorous exercise, can transiently elevate PSA. Age itself also plays a role, with PSA generally increasing with age. A thorough clinical evaluation, including digital rectal exam (DRE) and review of the patient's medical history, is essential to guide further investigations and differentiate between benign and malignant causes of an abnormal PSA. Explore how age-specific PSA reference ranges can aid in clinical decision-making.

Q: When should I consider ordering a free PSA test or a PSA velocity calculation in patients with consistently mildly elevated PSA results and a negative DRE?

A: In patients with consistently mildly elevated PSA results and a negative digital rectal exam (DRE), further evaluation is warranted to assess the risk of prostate cancer. Calculating the PSA velocity, which measures the rate of PSA increase over time, can be a valuable tool. A rapid PSA velocity may indicate a higher likelihood of malignancy. Furthermore, measuring the free PSA, which is the proportion of PSA not bound to proteins in the blood, can help improve the specificity of PSA testing. A lower percentage of free PSA can suggest a higher risk of prostate cancer. However, both free PSA and PSA velocity should be interpreted in conjunction with other clinical factors and not used in isolation. Consider implementing a risk stratification approach that incorporates age, family history, and other relevant factors when interpreting PSA results. Learn more about the latest guidelines for prostate cancer screening and early detection.

Quick Tips

Practical Coding Tips
  • Code elevated PSA with appropriate ICD-10
  • Document PSA units and reference range
  • Check medical necessity for PSA testing
  • Consider diagnosis specificity, eg. BPH
  • Review NCI guidelines for PSA coding

Documentation Templates

Patient presents with an abnormal prostate-specific antigen (PSA) level.  Differential diagnosis includes benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer.  The patient's PSA level was [insert value] ng/mL.  Review of systems includes [list relevant symptoms e.g., urinary frequency, urgency, hesitancy, nocturia, weak stream, pain with urination, lower back pain, etc.].  Physical exam findings include [document digital rectal exam findings e.g., prostate size, consistency, tenderness, nodules].  Patient's age, family history of prostate cancer, and ethnicity were considered in the assessment.  Given the abnormal PSA result, further investigation is warranted.  Ordered a repeat PSA test in [ timeframe ] to assess for fluctuations.  Discussed the implications of an elevated PSA and the need for additional diagnostic testing if the repeat PSA remains elevated.  Potential next steps include a free PSA test, PSA velocity calculation,  urinalysis, and consideration for a transrectal ultrasound with or without biopsy if clinically indicated. Patient education provided on prostate health, PSA testing, and the importance of follow-up.  Medical decision making (MDM) included discussion of the risks and benefits of further testing and treatment options. ICD-10 code R97.2 (Abnormal finding of prostate specific antigen [PSA]) is considered for this encounter. CPT codes for the evaluation and management (E/M) visit and any procedures performed will be documented separately.  Follow-up appointment scheduled for [date].